Our rationale for this sequencing was to use the IL-12 immunocytokine to inflame the tumor and promote an initial wave of tumor antigen release by pre-existing or newly recruited tumor-infiltrating leukocytes (TILs)11, followed by amplification of newly primed, tumor-specific T cells in the TDLNs by the IL-15 immunocytokine several days later22,23. Here, IL15 is linked to neoplasm.